Phase IB clinical study on the tolerance, safety and efficacy of darafenib, trametinib combined with irinotecan and cetuximab in advanced colorectal cancer with BRAF mutation
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
Interventions: experimental group:Darafenitumertinib plus iritiniconcetuximab Primary outcome(s): Maximum tolerated dose Study Design: Cross-sectional
创建时间：
2022-09-15
